Thursday, 26 Apr 2018

You are here

Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures

An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients. 

Investigators analyzed and compared 570 patients treated with etanercept (ETN), infliximab (INF) or adalimumab (ADL). Compared with SpA (n = 294) patients, RA patients (n = 276) were more likely to be female (80 vs 39%), older (56 vs 48 years), on DMARDs (83 vs 47%) and had slightly longer disease control for longer (202 vs 170 weeks) before their secondary TNFi failure.

No anti-drug antibodies were found with ETN, but were seen INF (27.1%) and ADA (29.0%) treated patients; 81% of these had no detectable serum drug levels.

While significiantly more SpA (31.3%) patients had anti-INF antibodies than RA (21.1%; P = 0.014), there were few patients patients developing anti-drug antibodies while on concomitant DMARDs (16.5%) compared to those on on monotherapy (26.4%; P < 0.05).

While these data show the potential impact of anti-drug antibodies in the loss of TNFi, efficacy, it appears to be a minor role (<30% of patients) and is not otherwise explained by concomitant DMARD use or the disorder under treatment.  Secondarly anti-TNF failure appears to have multiple etiologies.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

How to order for drug antibodies for those of us in community practice?

More Like This

Favorable Certolizumab Safety Profile in Pregnancy

Clowse and colleagues have published an extensive review of the certolizumab pegol (CZP) in pregnancy database, and found no evidence that CZP has a teratogenic effect or contributes to fetal harm when compared to the general population. 

Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept

The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk

A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.

Obesity Outweighs Psoriasis in Comorbidity Risk with Children

Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as  obesity.

Using claims data from Optum Laboratories Data Warehouse (150 million privately insured and Medicare enrollees), of 29 957 children with psoriasis were matched with a comparator cohort (children without psoriasis) and studied for the effects of psoriasis and obsesity. 

PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy

Rheumatoid arthritis patients who were younger and who had lower body mass index, Health Assessment Questionnaire (HAQ) scores, and less disease activity at baseline were most likely to achieve remission after combination etanercept (Enbrel) and methotrexate induction therapy, a post hoc analysis of the PRESERVE trial found.